The research study is testing an investigational product called TAVO101 designed specifically for people diagnosed with moderate to severe atopic dermatitis (eczema),
TAVO101 is a monoclonal antibody which is a large protein that binds to substances in the body and mimics the immune system’s usual response to these substances. TAVO101 is administered intravenously (into a vein with a needle). The main purpose of this research study is to learn if TAVO101 can help potentially reduce itching, redness, and improve skin health.
Anticipated date enrolment will close: November 2024
Ethics
All research in Australia involving human participants is reviewed by an independent group called a Human Research Ethics Committee (HREC). The ethical aspects of this research study have been approved by the Royal Melbourne Hospital HREC.
This study is being carried out according to the National Statement on Ethical Conduct in Human Research (2007). This statement protects the interests of people who agree to participate in human research studies.